FDA chief backs alternate method for injecting Bavarian Nordic's monkeypox shot
Reuters
Published Aug 11, 2022 12:43PM ET
(Reuters) - The U.S. Food and Drug Administration chief on Thursday defended a plan to administer Bavarian Nordic's monkeypox shot intradermally after the company raised doubts about the safety of the method, citing a lack of data.
The company had on Tuesday said there was some evidence that a shot of Jynneos between the layers of the skin could result in increased reactions compared to the approved method of injecting it underneath the skin.
FDA chief Robert Califf, however, backed the method saying while the intradermal administration led to some mild-to-moderate side effects, it produced a similar immune response to injecting the vaccine below the skin.
"In authorizing an unapproved use of an already approved product, the FDA is ensuring the vaccine meets high standards for safety, immune response and manufacturing quality," Califf tweeted. (https://
The U.S. health regulators had on Monday authorized the emergency use of the shot by recommending an alternate method of use, which would result in splitting a single vial of Jynneos into five doses.
"This may have a negative impact on vaccine uptake and coverage," the company had said in a letter to the FDA on Tuesday.
The company is also testing the potency of doses that the government had bought earlier and is stored in the Strategic National Stockpile to see if they can be used to fight the current outbreak.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.